Dopaminergic mechanism of imipramine action in an animal model of depression

Antidepressant effects of standardized extract of Commiphora mukul Engl. in olfactory bulbectomized rats

“…The increase in 24-h food intake shown by OBX rats in this study was in line with earlier results of OBX (McElroy et al 2004;McElroy et al 2005). In the present study, HECM treatment showed protective OBX rats from the hyperphagia (increased food intake), which resembled to the effects of standard antidepressants such as fluoxetine (Slotkin et al 2000), imipramine (Muscat et al 1990), desipramine (Nobrega and Coscina 1987), and thus confirming antidepressant potential of HECM in the OBXinduced rats. These effects of HECM can be mediated by numerous mechanisms.…”

Effects of Long-term Acetyl-L-carnitine Administration in Rats I. Increased Dopamine Output in Mesocorticolimbic Areas and Protection toward Acute Stress Exposure

“…These rats also show a decrease of D 2 DA receptor binding and mRNA levels in mesolimbic areas (Papp et al 1994;Dziedzicka-Wasylewska et al 1997), and a blunted phasic DA response to a feeding of palatable food in the NAcS and in the mPFC (Di Chiara and Tanda 1997). Both the behavioral and neurochemical changes induced by unavoidable stress exposure in the learned helplessness or CMS paradigms could be reversed by the chronic administration of classical antidepressant drugs (Muscat et al 1990(Muscat et al , 1992Petty et al 1992Petty et al , 1994Papp et al 1994Papp et al , 1996Di Chiara and Tanda 1997;Dziedzicka-Wasylewska et al 1997). Antidepressant compounds also revert the chronic escape deficit, and the drugs that we have tested in this paradigm, such as imipramine, fluoxetine, clomipramine, phenelzine, reboxetine, and a total extract of Hypericum perforatum, reinstated an avoidance response within three weeks of continuous treatment (Gambarana et al 1995a(Gambarana et al , 1999cGambarana, unpublished results).…”

The antipsychotic drug pimozide inhibits cell growth in prostate cancer through suppression of STAT3 activation

“…Since pimozide had relatively low side-effect and a broad spectrum of molecular targets, pimozide has been used to treat other diseases during the past 20 years, including monosymptomatic hypochondriacal psychoses, body dysmorphic disorder, metastatic melanoma, trichotillomania, and trigeminal and postherpetic neuralgia (23). Previous studies show that pimozide is a well-known antagonist of serotonin 5HT7 receptors (K i = 0.5 nM) for treating anti-depressant effect and of dopamine receptor D2 (D2R) (K i =0.33 nM) for treating schizophrenia (24)(25)(26). However, in the present study, it is reported that pimozide shows potential for use as a new anticancer agent for treating prostate cancer.…”